MRI Data Supports Novantrone Multiple Sclerosis Progression Claim - Cmte.

Novantrone's claim to slow progression in multiple sclerosis is supported by data based on magnetic resonance imaging surrogate endpoints, FDA's Peripheral and Central Nervous System Drugs Advisory Committee said Jan. 28.